8:30 am Microbiome Leaders Panel Discussion

9:30 am Gut Microbiome Endgame: Ramping up cGMP Program Design to Ensure Regulatory Preparedness for Microbiome Products

10:00 am Shotgun Sequencing & Strain-Level Analysis: Study Design for Pre-Clinical & Clinical Development

10.30 am Morning Refreshments & Speed Networking

Track A: Pre-Clinical Development & Mechanistic Analysis of Microbiome-based Therapeutics

Track B: Clinical Translation, Manufacturing and Commercialization of Microbiome-based Therapeutics

Track C: Microbiome-based Biomarkers, Bioinformatics and Patient Stratification

Complexities of Identifying Novel Live Biotherapeutic

 

11.30 Discovery and Development of Rationally Selected Consortia of Live Microbial Biotherapeutics Based on Disease Relevant Mechanisms

Jackie Papkoff, Chief Scientific Officer, Assembly Bioscien

Clinical Learnings of Live Biotherapeutics

 

11.30 C difficile Infection and Microbiome Therapeutics: The Importance of Understanding Your Disease Target

Barbara McGovern MD, VP Medical Affairs, Seres Therapeutics

Identifying and Validating Microbiome-based Biomarkers

 

11.30 Biomarkers for Risk Stratification and Treatment Response: Critical Considerations for Microbiome-Targeted Drug Development

Gerard Honig, Associate Director, Research Innovation, Crohn’s & Colitis Foundation

12.00 Targeting Host Inflammation and Immunity with Microbiome Therapeutics

Matthew Henn, Chief Scientific Officer, Seres Therapeutics

12.00 A Human-First Discovery Approach: Leveraging Clinical Data to Identify Microbial Communities Driving Positive Clinical Outcomes

Sonia Timberlake, VP Research, Finch Therapeutics

12.00 Novel Machine Learning Approach to Microbiome Based Biomarker Discovery

Assaf Oron, Chief Business Officer, BiomX

 

12.30 Bioinformatic Analysis of Microbial Communities for Patient Stratification and Rational Design of Live Biotherapeutic Product

Daniel van der Lelie, Chief Scientific Officer, Gusto Global

 

13.00 Next Generation Microbiome Profiling

Tuval Ben-Yehezkel, CEO, Loop Genomics

12.30 Prevention of Recurrent Clostridium Difficile Following Treatment with Microbiota based Therapy: Clinical Results and Considerations

Ken Blount, CSO, Rebiotix

 

 

 

 

12.30 Panel Discussion: Reviewing the Role of the Human Microbiome in Biomarker Discovery & Development

Gerard Honig, Associate Director, Research Innovation, Crohn’s & Colitis Foundation

Bruce Roberts, Chief Scientific Officer, Vedanta Biosciences

Matthew Henn, Chief Scientific Officer, Seres Therapeutics

Assaf Oron, Chief Business Officer, BiomX

Microbiome Chemistry Small Molecules

 

14.00 Small Molecule Approaches to Target the Gut-Brain Axis

David Donabedian, Co-Founder & CEO, Axial Biotherapeutics

 

14.30 Outlining Enterome’s Onco-Mimics Program: Microbiome-Derive Immunotherapy for Treatment of Cancers

Christophe Bonny, CSO, Enterome 

 

15.00 Leading a Chemistry-Driven Approach to Targeting the Microbiome

Johan van Hylckama Vlieg, CSO, Kaleido Biosciences

 

15.30 Delivery, Survival, Engraftment & Activity of LBPs in the GI Tract

Massimo Marzorati, CEO, ProDigest

Designing and Executing Clinical Trials – A Clinician’s Perspective

 

14.00 Designing and Executing FMT Clinical Trials

Jessica Allegretti MD, Director Clinical Trials, Brigham & Women’s Hospital

 

14.30 What Does it Take to Think and Design a Clinical Trial for Live Biotherapeutics?

Sahil Khanna MD, Associate Professor of Medicine & Consultant, Mayo Clinic

 

15.00 Presenting Case Vignettes to Highlight the Critical Importance of Good Clinical Practice, Education and Safety Monitoring in FMT

Majdi Osman MD, Clinical Program Director, OpenBiome

 

15.30 Presentation from Wacker Biotech

Biomarker Applications in Drug Discovery and Patient Stratification

 

14.00 From Association to Function to Action 

Aaron Del Duca, VP Microbiome Platform, Day Two

 

14.30 Enabling Precision Medicine and Discovery of Novel Microbiome-based Therapeutics

Ryan Toma, Research Scientist, Viome

 

15.00 Exploring & Modeling the Impact of the Microbiome on Vaccine Response

Geoffrey Hannigan, Associate Principal Scientist, Merck Exploratory Science Center

 

15.30 Early Break for Afternoon Refreshments

 

15.40 Afternoon Refreshments & Networking

Track A: Pre-Clinical Development & Mechanistic Analysis of Microbiome-based Therapeutics

Track B: Clinical Translation, Manufacturing and Commercialization of Microbiome-based Therapeutics

Track C: Microbiome-based Biomarkers, Bioinformatics and Patient Stratification

New Approaches to Pre-Clinical Assessment of Microbiome-targeting Therapeutics

 

16.00 Translatability of In Vivo Models in Microbiome Research

Betty Theriault DVM, Assistant Professor, University of Chicago

 

16.30 Born To Be Wild: Uutilizing the Common Link Among Mammals to Improve Translational Research Models in Microbiome Research

Stephan Patrick Rosshart, Principal Investigator & Group Leader Translational Microbiome Research, University Medical Center Freiburg

 

17.00 An Ecological Framework to Understand the Efficacy of Fecal Microbiota Transplantation

Yang-Yu Liu, Assistant Professor of Medicine, Harvard Medical School

 

 

 

Manufacturing and Scaling the Microbiome

 

16.00 Scale Up & GMP Manufacture of LBPs

Jason Ryan, Head of Upstream, Luina Bio

 

16.30 Manufacturing Commensal Microbes for Treatment of The Microbiome

John Aunins, Chief Technology Officer, Seres Therapeutics

 

17.00 Development of Oral LBPS – a CDMOs Perspective

Ryan Wilson, Head of Live-Bioprogrammes, Quay Pharma

 

17.30 Overcoming Hurdles in the Development of Live Biotherapeutic Products

Stacy Burns-Guydish, VP Biotherapeutics Development & Manufacturing, List Laboratories

 

Developing Microbiome Diagnostics in Cancer & IBD

 

16.00 Leveraging Bacterial Risk Factors to Improve Pediatric Asthma Prediction

Ricardo Valladares, VP Research & Development, Siolta Therapeutics

 

16.30 Leveraging the Microbiome to Deliver Safer and More Efficacious Drug Therapies

Marcus Rauch, Chief Scientific Officer, AlphaBiomics

 

17.00 Developing a Non-Invasive Diagnostic for the Early Detection of Colon Polyps and Colorectal Cancer Using the Human Microbiome

Keri Donaldson, dCEO, Prescient Metabiomics

 

17.30 The Blood Microbiome: New Source of Biomarkers for Infectious and Cardiometabolic Diseases

Benjamin Lelouvier, Chief Scientific Officer, Vaiomer

5:40 pm Challenge Masterminds Session

6:00 pm Evening Drinks Reception and Scientific Poster Session

7:00 pm Close of Conference Day One